{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:17:42Z","timestamp":1790511462657,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011284","name":"Valeant Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clml.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T21:49:35Z","timestamp":1589147375000},"page":"744-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study"],"prefix":"10.1016","volume":"20","author":[{"given":"Frederick","family":"Lansigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Pinter-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-751X","authenticated-orcid":false,"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Bellm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.05.001_bib1","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2020.05.001_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamadermatol.2013.7747","article-title":"Outcomes after diagnosis of mycosis fungoides and Sezary syndrome before 30 years of age: a population-based study","volume":"150","author":"Ai","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clml.2020.05.001_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.001_bib4","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.001_bib5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2020.05.001_bib6","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.001_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000121002","article-title":"Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine","volume":"73","author":"Awar","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2020.05.001_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2007.08008.x","article-title":"Transformed mycosis fungoides: clinicopathological features and outcome","volume":"157","author":"Barberio","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2020.05.001_bib9","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.001_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clml.2015.11.010","article-title":"Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides","volume":"16","author":"Talpur","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.05.001_bib11","first-page":"2212","article-title":"Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas","volume":"95","author":"Vergier","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.001_bib12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.05.001_bib13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2013.09.007","article-title":"Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium","volume":"70","author":"Kadin","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2020.05.001_bib14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A\u00a0prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.05.001_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.001_bib16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s12253-015-9897-8","article-title":"Altered microRNA expression in folliculotropic and transformed mycosis fungoides","volume":"21","author":"Marosvari","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.clml.2020.05.001_bib17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/gcc.20469","article-title":"Common chromosomal abnormalities in mycosis fungoides transformation","volume":"46","author":"Prochazkova","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2020.05.001_bib18","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","article-title":"A\u00a0phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders","volume":"15","author":"Duvic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.05.001_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:19Z","timestamp":1761870919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020302172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2152265020302172"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}